Buprenorphine

Major

Buprenorphine Levodopa Oral Inhalation Inbrija An increased risk of CNS depression Details Buprenorphine Levofloxacin Injection Levaquin An increased risk of QT interval prolongation Details Buprenorphine Linezolid Injection Zyvox An increased risk of serotonin syndrome or opioid-related toxicity Details Buprenorphine Lithium Carbonate Lithobid Increased risk of serotonin syndrome Details Buprenorphine Metoclopramide Injection Gimoti Increased risk of CNS depression Details Buprenorphine Metoclopramide Nasal Spray Gimoti Increased risk of CNS depression Details Buprenorphine Metronidazole Injection Flagyl An increased risk of QT interval prolongation Details Buprenorphine Metronidazole Topical MetroCream® An increased risk of QT interval prolongation Details Buprenorphine Metronidazole Vaginal MetroGel® Vaginal An increased risk of QT interval prolongation Details Buprenorphine Midazolam Nasal Spray Nayzilam An increased risk of CNS depression and respiratory depression Details Buprenorphine Midazolam Injection Nayzilam An increased risk of CNS depression and respiratory depression Details Buprenorphine Morphine Injection Astramorph® PF Reduced analgesic effect or precipitation of withdrawal symptoms, and an increased risk of serotonin syndrome Details Buprenorphine Moxifloxacin Injection Avelox An increased risk of QT interval prolongation Details Buprenorphine Moxifloxacin Ophthalmic Moxeza® An increased risk of QT interval prolongation Details Buprenorphine Nafarelin Nasal Spray Synarel An increased risk of QT interval prolongation Details Buprenorphine Nafcillin Injection Unipen® Injection Reduced buprenorphine exposure and reduced efficacy of buprenorphine Details Buprenorphine Nalbuphine Injection Nubain® Reduced analgesic effect or precipitation of withdrawal symptoms, and an increased risk of serotonin syndrome and respiratory depr... Details Buprenorphine Octreotide Injection Bynfezia An increased risk of QT interval prolongation Details Buprenorphine Ofloxacin Ophthalmic Ocuflox An increased risk of QT interval prolongation Details Buprenorphine Ofloxacin Otic Floxin® Otic An increased risk of QT interval prolongation Details Buprenorphine Olodaterol Oral Inhalation Striverdi An increased risk of QT interval prolongation and an increased risk of ventricular arrhythmias Details Buprenorphine Oxaliplatin Injection Eloxatin® Increased risk of QT-interval prolongation Details Buprenorphine Palonosetron Injection Aloxi® An increased risk of serotonin syndrome Details

Moderate

Buprenorphine Brimonidine Alphagan Explained An increased risk of CNS depression Details Buprenorphine Carbachol Isopto Carbachol Explained An increased risk of CNS depression Details Buprenorphine Clonidine Duraclon Explained An increased risk of sedation and somnolence Details Buprenorphine Desmopressin DDAVP Explained Increased risk of water intoxication with hyponatremia Details Buprenorphine Ganaxolone Ztalmy Explained An increased risk of somnolence and sedation Details Buprenorphine Mavacamten Camzyos Explained Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Buprenorphine Rilzabrutinib Wayrilz Explained Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Buprenorphine Grapefruit Juice Explained Increased plasma concentrations of buprenorphine Details Buprenorphine Clonidine Transdermal Patch Catapres An increased risk of sedation and somnolence Details Buprenorphine Desmopressin Nasal Concentraid® Increased risk of water intoxication with hyponatremia Details